Bristol Vanlev Limited Distribution Necessary For Approval, Cmte. Says
Executive Summary
Bristol's Vanlev angioedema risk management program should require a limited distribution system to support approval of the antihypertensive agent, FDA's Cardiovascular & Renal Drugs Advisory Committee recommended July 19